HER2-positive gastric cancer
Clinical trials for HER2-positive gastric cancer explained in plain language.
Never miss a new study
Get alerted when new HER2-positive gastric cancer trials appear
Sign up with your email to follow new studies for HER2-positive gastric cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a targeted therapy tame hard-to-treat stomach and esophageal cancers?
Disease control Not yet recruitingThis study looks at how zanidatamab, a targeted drug for HER2-positive gastroesophageal cancer, is used in real-world clinical practice. Researchers will track about 300 adults with advanced or metastatic disease who are starting zanidatamab as their first treatment, recording pa…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Targeted antibody combo aims to shrink HER2-Positive stomach cancers before surgery
Disease control Not yet recruitingThis trial investigates whether adding the targeted antibody zanidatamab to standard chemotherapy can shrink HER2-positive stomach or gastroesophageal junction cancers before surgery. It includes two groups: people with locally advanced cancer that has not spread, and those with …
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase 2 • Sponsor: Zhifeng Zhao, PhD • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for stomach cancer: drug cocktail targets tough tumors
Disease control Not yet recruitingThis study tests a new drug called KN026, combined with chemotherapy and an immunotherapy (enlonstobart), as a first treatment for people with HER2-positive advanced stomach cancer that cannot be removed by surgery. About 490 participants will be split into groups to compare this…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase 2/3 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC